A new study links gut microbes with the severity and course of chronic systolic heart failure. It identifies research leads, not evidence that taking a probiotic treats heart failure.
Illustrative laboratory photograph, not the study laboratory. Photo: Testalize.me / Unsplash.
What changed
Published September 24, 2026, the study compared 59 adults with heart failure caused by nonischemic cardiomyopathy with 50 healthy participants. Higher Bifidobacterium abundance was associated with clinical improvement in follow-up analyses. Researchers also linked a microbial metabolite, indole-3-propionic acid, with milder disease.
How strong is the evidence?
Peer-reviewed human observational research, with laboratory experiments showing that some Bifidobacterium species can produce the metabolite. Participants were not randomized to a probiotic treatment. Association cannot establish that changing bacteria causes recovery.
What remains uncertain
The single-center sample was small and predominantly white; the heart-failure group was mostly male. Medication effects remain difficult to separate from disease effects. People with treated diabetes were excluded. One author disclosed commercial advisory and founder roles.
Why it matters
The findings help prioritize future trials. They do not justify substituting supplements for established care, or assuming results apply to every form of heart disease.
Sources
Mamic and colleagues, Nature Cardiovascular Research. Original study published September 24, 2026; no separate news report used.
